Plozalizumab (anti-CCR2), CCR2 抗体

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 大鼠(Rat), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175634-100μg	100μg	现货
Ab175634-1mg	1mg	现货
Ab175634-5mg	5mg	现货
Ab175634-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: CCR2

Accession#:P41597 (1) CCR2 (1) CCR2 Antibody (1) Class A GPCR (8201) Gene ID:729230 (1)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Plozalizumab (anti-CCR2), CCR2 抗体
别名	洛扎利珠单抗
英文别名	C C chemokine receptor type 2 antibody \| C C CKR 2 antibody \| C-C chemokine receptor type 2 antibody \| C-C CKR-2 antibody \| CC chemokine receptor type 2 antibody \| CC CKR 2 antibody \| CC-CKR-2 antibody \| CCCKR2 antibody \| CCR 2 antibody \| CCR-2 antibody \|
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CCR2
种属反应性	人(Human),大鼠(Rat),小鼠(Mouse),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	CCR2 抗体

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.5 kDa (Light Chain) & 50.4 kDa (Heavy Chain), under reducing conditions; 180.8 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH5.0.
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1610761-46-0
分子类型	抗体

关联靶点（人）

CCR2 Tchem CC 趋化因子受体 2 型(C-C chemokine receptor type 2) (0 活性数据)

点击查看靶蛋白信息： CCR2

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Plozalizumab (anti-CCR2) (Ab175634)

Plozalizumab (anti-CCR2) (Ab175634) - Flow Cytometry
Flow Cytometry analysis of THP-1 cells labelling CCR2 (red) with Plozalizumab (anti-CCR2) (Ab175634). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: Plozalizumab (anti-CCR2) (Ab175634)

Plozalizumab (anti-CCR2) (Ab175634) - SEC
The purity of Plozalizumab (anti-CCR2) (Ab175634) is more than 95% verified by HPLC.

ELISA: Plozalizumab (anti-CCR2) (Ab175634)

Plozalizumab (anti-CCR2) (Ab175634) - Flow Cytometry
Flow Cytometry analysis of Human CCR2 HEK293 cells can bind Plozalizumab (anti-CCR2) (Ab175634) with the EC₅₀ of 50 nM.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ24F0911051	分析证书	Ab175634
ZJ24F0911050	分析证书	Ab175634
ZJ24F0911049	分析证书	Ab175634

引用文献

1. Forbes IT, Cooper DG, Dodds EK, Hickey DM, Ife RJ, Meeson M, Stockley M, Berkhout TA, Gohil J, Groot PH, Moores K.. (2000) CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.. Bioorg Med Chem Lett, 10 (16): (1803-1806). [PMID:10969972] [10.1016/s0960-894x(00)00347-4]
2. Naya A, Sagara Y, Ohwaki K, Saeki T, Ichikawa D, Iwasawa Y, Noguchi K, Ohtake N.. (2001) Design, synthesis, and discovery of a novel CCR1 antagonist.. J Med Chem, 44 (9): (1429-1435). [PMID:11311066] [10.1021/jm0004244]
3. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA. (1997) High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.. J Clin Invest, 100 (5): (1137-43). [PMID:9276730]
4. Coulin F, Power CA, Alouani S, Peitsch MC, Schroeder JM, Moshizuki M, Clark-Lewis I, Wells TN. (1997) Characterisation of macrophage inflammatory protein-5/human CC cytokine-2, a member of the macrophage-inflammatory-protein family of chemokines.. Eur J Biochem, 248 (2): (507-15). [PMID:9346309]
5. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. (1994) Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.. Proc Natl Acad Sci USA, 91 (7): (2752-6). [PMID:8146186]
6. Lüttichau HR, Clark-Lewis I, Jensen PØ, Moser C, Gerstoft J, Schwartz TW. (2003) A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6.. J Biol Chem, 278 (13): (10928-33). [PMID:12554737]
7. Wong LM, Myers SJ, Tsou CL, Gosling J, Arai H, Charo IF. (1997) Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking.. J Biol Chem, 272 (2): (1038-45). [PMID:8995400]
8. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R et al.. (1997) Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.. Science, 277 (5328): (959-65). [PMID:9252328]
9. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, Dankwardt J et al.. (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle.. J Biol Chem, 275 (33): (25562-71). [PMID:10770925]
10. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G et al.. (1998) HIV-1 Tat protein mimicry of chemokines.. Proc Natl Acad Sci USA, 95 (22): (13153-8). [PMID:9789057]
11. Carter PH, Liu RQ, Foster WR, Tamasi JA, Tebben AJ, Favata M, Staal A, Cvijic ME, French MH, Dell V et al.. (2007) Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe.. Proc Natl Acad Sci USA, 104 (16): (6846-51). [PMID:17428923]
12. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, Greenberg J, Weiszmann J, Ge H, Tian H et al.. (2010) The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.. Bioorg Med Chem Lett, 20 (2): (493-8). [PMID:20005104]
13. Zheng Y, Qin L, Zacarías NV, de Vries H, Han GW, Gustavsson M, Dabros M, Zhao C, Cherney RJ, Carter P et al.. (2016) Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.. Nature, 540 (7633): (458-461). [PMID:27926736]
14. Santella 3rd JB, Gardner DS, Duncia JV, Wu H, Dhar M, Cavallaro C, Tebben AJ, Carter PH, Barrish JC, Yarde M et al.. (2014) Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.. J Med Chem, 57 (18): (7550-64). [PMID:25101488]
15. Buntinx M, Hermans B, Goossens J, Moechars D, Gilissen RA, Doyon J, Boeckx S, Coesemans E, Van Lommen G, Van Wauwe JP. (2008) Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.. J Pharmacol Exp Ther, 327 (1): (1-9). [PMID:18599682]
16. Angst D, Gessier F, Janser P, Vulpetti A, Wälchli R, Beerli C, Littlewood-Evans A, Dawson J, Nuesslein-Hildesheim B, Wieczorek G et al.. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 63 (10): (5102-5118). [PMID:32083858]
17. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al.. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.. J Med Chem, 62 (15): (6876-6893). [PMID:31282155]
18. Ann Kathrin Strunz,Annelien J M Zweemer,Christina Weiss,Dirk Schepmann,Anna Junker,Laura H Heitman,Michael Koch,Bernhard Wünsch. (2015-03-15) Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2).. Bioorganic & medicinal chemistry, 23 ((14)): (4034-4049). [PMID:25766632]
19. De Lucca GV, Kim UT, Vargo BJ, Duncia JV, Santella JB, Gardner DS, Zheng C, Liauw A, Wang Z, Emmett G, Wacker DA, Welch PK, Covington M, Stowell NC, Wadman EA, Das AM, Davies P, Yeleswaram S, Graden DM, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS.. (2005) Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.. J Med Chem, 48 (6): (2194-2211). [PMID:15771462] [10.1021/jm049530m]
20. Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H, Schlapbach A, Waelchli R.. (2005) Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.. Bioorg Med Chem Lett, 15 (23): (5160-5164). [PMID:16198561] [10.1016/j.bmcl.2005.08.057]
21. Bruno O, Brullo C, Bondavalli F, Schenone S, Ranise A, Arduino N, Bertolotto MB, Montecucco F, Ottonello L, Dallegri F, Tognolini M, Ballabeni V, Bertoni S, Barocelli E.. (2007) Synthesis and biological evaluation of N-pyrazolyl-N'-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis.. J Med Chem, 50 (15): (3618-3626). [PMID:17608466] [10.1021/jm0704402]
22. Xia M, Hou C, DeMong DE, Pollack SR, Pan M, Brackley JA, Jain N, Gerchak C, Singer M, Malaviya R, Matheis M, Olini G, Cavender D, Wachter M.. (2007) Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.. J Med Chem, 50 (23): (5561-5563). [PMID:17929797] [10.1021/jm070902b]
23. Lagu B, Gerchak C, Pan M, Hou C, Singer M, Malaviya R, Matheis M, Olini G, Cavender D, Wachter M.. (2007) Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.. Bioorg Med Chem Lett, 17 (15): (4382-4386). [PMID:17587570] [10.1016/j.bmcl.2007.01.115]
24. Srikanth K, Nair PC, Sobhia ME.. (2008) Probing the structural and topological requirements for CCR2 antagonism: holographic QSAR for indolopiperidine derivatives.. Bioorg Med Chem Lett, 18 (4): (1450-1456). [PMID:18226895] [10.1016/j.bmcl.2007.12.072]
25. Nair PC, Srikanth K, Sobhia ME.. (2008) QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors.. Bioorg Med Chem Lett, 18 (4): (1323-1330). [PMID:18258426] [10.1016/j.bmcl.2008.01.023]
26. Sohy D, Parmentier M, Springael JY.. (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.. J Biol Chem, 282 (41): (30062-30069). [PMID:17715128] [10.1074/jbc.m705302200]
27. Merritt JR, Liu J, Quadros E, Morris ML, Liu R, Zhang R, Jacob B, Postelnek J, Hicks CM, Chen W, Kimble EF, Rogers WL, O'Brien L, White N, Desai H, Bansal S, King G, Ohlmeyer MJ, Appell KC, Webb ML.. (2009) Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.. J Med Chem, 52 (5): (1295-1301). [PMID:19183043] [10.1021/jm801416q]
28. Trujillo JI, Huang W, Hughes RO, Rogier DJ, Turner SR, Devraj R, Morton PA, Xue CB, Chao G, Covington MB, Newton RC, Metcalf B.. (2011) Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.. Bioorg Med Chem Lett, 21 (6): (1827-1831). [PMID:21316220] [10.1016/j.bmcl.2011.01.052]
29. Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR, Simon RJ, Xu H, Baba K, Inagaki H, Ishiwata Y, Jomori T, Matsumoto Y, Miyachi A, Nakamura T, Okamoto M, Handel TM, Bernard CC.. (2011) Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.. J Med Chem, 54 (6): (1667-1681). [PMID:21341682] [10.1021/jm1012903]
30. Ukani R, Lewis TC, Day TP, Wu W, Malladi SS, Warshakoon HJ, David SA.. (2012) Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.. Bioorg Med Chem Lett, 22 (1): (293-295). [PMID:22104149] [10.1016/j.bmcl.2011.11.014]
31. Furlotti G, Alisi MA, Apicella C, Capezzone de Joannon A, Cazzolla N, Costi R, Cuzzucoli Crucitti G, Garrone B, Iacovo A, Magarò G, Mangano G, Miele G, Ombrato R, Pescatori L, Polenzani L, Rosi F, Vitiello M, Di Santo R.. (2012) Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands.. J Med Chem, 55 (22): (9446-9466). [PMID:23043420] [10.1021/jm300573d]
32. Smethurst CA, Bevan N, Brooks C, Emmons A, Gough PJ, Mookherjee C, Moores K, Peace S, Philp J, Piercy V, Watson SP, Zippoli M.. (2012) In vivo activity of an azole series of CCR2 antagonists.. Bioorg Med Chem Lett, 22 (23): (7252-7255). [PMID:23079519] [10.1016/j.bmcl.2012.09.020]
33. Subasinghe NL, Lanter J, Markotan T, Opas E, McKenney S, Crysler C, Hou C, O'Neill J, Johnson D, Sui Z.. (2013) A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.. Bioorg Med Chem Lett, 23 (4): (1063-1069). [PMID:23294701] [10.1016/j.bmcl.2012.12.017]
34. Abdel-Magid AF.. (2013) Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders.. ACS Med Chem Lett, 4 (4): (371-372). [PMID:24900677] [10.1021/ml400055e]
35. Hurevich M, Ratner-Hurevich M, Tal-Gan Y, Shalev DE, Ben-Sasson SZ, Gilon C.. (2013) Backbone cyclic helix mimetic of chemokine (C-C motif) receptor 2: a rational approach for inhibiting dimerization of G protein-coupled receptors.. Bioorg Med Chem, 21 (13): (3958-3966). [PMID:23706536] [10.1016/j.bmc.2013.03.019]
36. Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.. (2013) Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.. J Med Chem, 56 (20): (8049-8065). [PMID:24090135] [10.1021/jm401101p]
37. Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF.. (2013) Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors.. ACS Med Chem Lett, 4 (12): (1218-1223). [PMID:24900633] [10.1021/ml4003315]
38. Cherney RJ, Mo R, Yang MG, Xiao Z, Zhao Q, Mandlekar S, Cvijic ME, Charo IF, Barrish JC, Decicco CP, Carter PH.. (2014) Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.. Bioorg Med Chem Lett, 24 (7): (1843-1845). [PMID:24613378] [10.1016/j.bmcl.2014.02.013]
39. Vilums M, Zweemer AJ, Barmare F, van der Gracht AM, Bleeker DC, Yu Z, de Vries H, Gross R, Clemens J, Krenitsky P, Brussee J, Stamos D, Saunders J, Heitman LH, IJzerman AP.. (2015) When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists.. Eur J Med Chem, 93 (121-134). [PMID:25666912] [10.1016/j.ejmech.2015.01.063]
40. Qin LH, Wang ZL, Xie X, Long YQ.. (2018) Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy.. Bioorg Med Chem, 26 (12): (3559-3572). [PMID:29805075] [10.1016/j.bmc.2018.05.027]
41. Ortiz Zacarías NV, van Veldhoven JPD, Portner L, van Spronsen E, Ullo S, Veenhuizen M, van der Velden WJC, Zweemer AJM, Kreekel RM, Oenema K, Lenselink EB, Heitman LH, IJzerman AP.. (2018) Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.. J Med Chem, 61 (20): (9146-9161). [PMID:30256641] [10.1021/acs.jmedchem.8b00605]
42. Yamagami, S S, Tokuda, Y Y, Ishii, K K, Tanaka, H H and Endo, N N.. (1994) cDNA cloning and functional expression of a human monocyte chemoattractant protein 1 receptor.. Biochemical and biophysical research communications, (29): [PMID:8048929]
43. Polentarutti, N N and 7 more authors.. (1997) IL-2-regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4-kilobase transcript containing CCR2B and CCR2A sequences.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:9058802]
44. Aragay, A M AM and 6 more authors.. (1998) Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2.. Proceedings of the National Academy of Sciences of the United States of America, (17): [PMID:9501202]
45. Mummidi, S S and 11 more authors.. (1998) Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression.. Nature medicine, [PMID:9662369]
46. Mellado, M M and 8 more authors.. (1998) The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:9670957]
47. Preobrazhensky, A A AA and 6 more authors.. (2000) Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:11046064]
48. Terashima, Yuya Y and 11 more authors.. (2005) Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis.. Nature immunology, [PMID:15995708]
49. Muzny, Donna M DM and 113 more authors.. (2006) The DNA sequence, annotation and analysis of human chromosome 3.. Nature, (27): [PMID:16641997]
50. Sung, Ho Joong HJ, Kim, Yoon Suk YS, Kang, Hyereen H and Ko, Jesang J.. (2008) Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration.. Experimental & molecular medicine, (30): [PMID:18587271]
51. Tan, Joshua H Y JH and 10 more authors.. (2013) Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1).. The Journal of biological chemistry, (5): [PMID:23408426]
52. De Paula, V S VS and 6 more authors.. (2013) Structural basis for the interaction of human β-defensin 6 and its putative chemokine receptor CCR2 and breast cancer microvesicles.. Journal of molecular biology, (15): [PMID:23938203]
53. Esaki, Kaori K and 12 more authors.. (2014) Structural basis for the binding of the membrane-proximal C-terminal region of chemokine receptor CCR2 with the cytosolic regulator FROUNT.. The FEBS journal, [PMID:25283965]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Plozalizumab (anti-CCR2), CCR2 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器